<DOC>
	<DOCNO>NCT00021151</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Compassionate use refers provide drug patient humanitarian ground drug receive official approval . PURPOSE : Compassionate use Campath-1H treat patient refractory prolymphocytic leukemia chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Compassionate Use Campath-1H Treating Patients With Refractory Prolymphocytic Leukemia Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Expand access Campath-1H patient refractory prolymphocytic leukemia chronic lymphocytic leukemia . OUTLINE : Patients receive Campath-1H IV 2 hour day 1 , 3 , 5 . Treatment repeats weekly 4-12 week absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : Not specify</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Confirmed prolymphocytic leukemia ( PLL ) chronic lymphocytic leukemia ( CLL ) PLL fail least 1 prior regimen CLL fail prior fludarabine , define : No response Disease progression receive therapy OR Relapse within 6 month completion last dose PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) ( unless secondary direct liver infiltration CLL ) Renal : Creatinine great 2 time ULN Other : HIV negative No active infection No severe concurrent disease No mental disorder No prior allergic reaction rat mousederived CDRgrafted humanize monoclonal antibody Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy No concurrent cytotoxic therapy Endocrine therapy : Not specify Radiotherapy : At least 3 week since prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>prolymphocytic leukemia</keyword>
</DOC>